My clinical approach emphasizes the use of combined modality therapies to treat cancer. By tailoring combined radiation-drug treatment plans to fit the individual cancer patient, we maximize therapeutic efficacy and reduce toxic exposure. I am also actively investigating how best to use novel imaging and radiotherapy techniques to improve radiation treatments.
I enjoy working with world-class colleagues in surgery and oncology at the OSUCCC – James. I’m actively involved in preclinical research and clinical trial design. These trials allow us to determine which drug-radiation combinations are most effective in overcoming treatment resistance and improving patient survival rates.
I’ve been invited to speak at national and international conferences and universities. I also have several published articles in medical journals including Cancer Research, Journal of Clinical Investigation and Molecular Cell.
- Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2016
Pennsylvania State University College of Medicine
University of Pennsylvania Medical Center
7/1/2007 - 6/30/2011
Specialties and conditions I treat
- Radiation Oncology
- Hodgkin Lymphoma
- Lung Cancers
- Soft Tissue Cancers
- Connective and Soft Tissue Cancers
- Plasma Cell Cancers
- Radiotherapy, Intensity-Modulated
- Whole-Body Irradiation
Locations where I practice
The James Cancer Hospital and Solove Research Institute
More about my work
American Board of Radiology (Subspecialty: Radiation Oncology)
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Welliver has reported no financial relationships with medical device, research and/or drug companies.